Wednesday, June 18, 2025 6/18/2025

Developing novel RPPA for the detection of metastatic prostate cancer

Award Number: R41CA210772
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 09/01/2016
PERIOD OF PERFORMANCE END DATE: 08/31/2019

Group Awards By:

View Award Description

Developing novel RPPA for the detection of metastatic prostate cancer - PROJECT SUMMARY Reverse-phase protein array (RPPA) has emerged as a promising antibody-based highly quantitative proteomic technology suitable for profiling proteins in hundreds to thousands of patient samples. The throughput, sensitivity, and cost effectiveness of RPPA, together with its ability to deal with minuscule sample amounts, have propelled applications of the technology in basic, preclinical and clinical research fields. The technology, which relies heavily on the paucity of high-quality monospecific antibodies, however, is only centered on detecting a few key signaling molecules due to limited availability of high quality phosphospecific antibodies. In this NIH STTR Phase I study, we will develop a novel RPPA platform based on metal ion-functionalized soluble nanopolymers into commercial products for sensitive, high throughput profiling of signaling molecules without the limitation of antibodies. The novel RPPA platform will be applied to distinguish aggressive from indolent human prostate tumors in xenograft mouse models. We hypothesis that prostate cancer can be classified by measuring phosphorylation changes on key oncogenes and thus a RPPA platform can be used as a discovery and preclinical tool to distinguish aggressive from indolent tumors. The following aims will be completed. Aim #1: Optimization of functionalized RPPA for capture and detection of phosphopropteins. Aim #2: Pathway-activation profiling in indolent and aggressive prostate cancer xenograft mouse models. By the completion of Phase I study, we expect that an analytical platform can be established with high sensitivity, wide dynamic range, excellent reproducibility, and affordable cost.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2020 ( Subtotal = $0 )
2020	2016	TYMORA ANALYTICAL OPERATIONS, LLC	1201 CUMBERLAND AVE STE 209	WEST LAFAYETTE	IN	47906	TIPPECANOE	USA	Cancer Detection and Diagnosis Research	000	1	1/19/2020	NEW	$0
														Subtotal = $0

Issue Date FY: 2018 ( Subtotal = $2,000 )
2018	2018	TYMORA ANALYTICAL OPERATIONS, LLC	3495 KENT AVE STE E400	WEST LAFAYETTE	IN	47906	TIPPECANOE	USA	Cancer Detection and Diagnosis Research	001	1	9/14/2018	SUPPLEMENT FOR EXPANSION	$2,000
2018	2016	TYMORA ANALYTICAL OPERATIONS, LLC	3495 KENT AVE STE E400	WEST LAFAYETTE	IN	47906	TIPPECANOE	USA	Cancer Detection and Diagnosis Research	000	1	8/31/2018	NEW	$0
														Subtotal = $2,000

Issue Date FY: 2016 ( Subtotal = $225,000 )
2016	2016	TYMORA ANALYTICAL OPERATIONS LLC	1281 WIN HENTSCHEL BOULEVARD	WEST LAFAYETTE	IN	47906	TIPPECANOE	USA	Cancer Detection and Diagnosis Research	000	1	8/31/2016	NEW	$225,000
														Subtotal = $225,000

Grand Total All Awards = $227,000

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Developing novel RPPA for the detection of metastatic prostate cancer

Award Number: R41CA210772

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 09/01/2016

PERIOD OF PERFORMANCE END DATE: 08/31/2019

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer